U.S. Markets open in 1 hr 32 mins

Endo International plc (ENDP)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
11.67-0.71 (-5.74%)
At close: 4:00PM EDT
People also watch
  • Closing the manufacturing plant in North Alabama is a good thing. Tax savings and employee reduction. All good for the bottom line. Can't really understand why the stock takes a hit on this kind of news.
  • I thought OCLR was manipulated to the extreme ... ENDP is manipulated far worse. This is so oversold it's downright comical.
  • Not really comfortable with a restructuring announcement immediately before the earnings release....
  • Buy under $10 under $8. Might be time to move on. Stock was already a dicey proposition. But closing manufacturing in the south in the current political environment seems to take a chapter out of one of my favorite books from college" Moron management and the investors ruined by them"I'm done. GoodbyeAnd, #$%$ Endo!!!!!!
  • Good luck if you stay in this overnight. I fear under $10 in a blink of an eye
  • KTOV = Mcap $16 Mil /Cash $17 Mil / ULTRA Low float / NDA submission for potential Blockbuster this Quarter = 20 BAGGER ..ONE OF THE BIGGEST BIOTECH OPPORTUNITY EVER ! Thank me later guys

    Kitov Pharma (KTOV)

    Market Cap: $17 M
    Cash $17 M
    Price: $1.50

    Shares Out: 10.6 Million

    Kitov Pharmaceuticals Initiates NDA Filing for KIT-302 as a Treatment for Osteoarthritis and Hypertension

    Kitov Expects to Submit an NDA for KIT-302 in the Third Quarter 2017.Kitov announced that it began the process of compiling the documents necessary to file an NDA for its lead asset KIT-302 as a treatment for patients who experience both osteoarthritis and hypertension. The Company hired Parexel International Corporation, a clinical research organization, to digitalize and formally submit its NDA application. Kitov expects the filing to occur during the third quarter of 2017, with a potential FDA approval during the second quarter of 2018.

    KIT-302 is a combination drug that treats osteoarthritis pain and hypertension simultaneously

    Primary efficacy endpoint achieved Lead drug candidate KIT-302 achieved its primary efficacy endpoint in a pivotal Phase III trial

    Marketing potential Pipeline candidates address large, multi-billion dollar markets

  • http://thewolftrader.com/?s=ENDP has an alert for $ENDP. Did anyone happen to see it as well? Looking for some good positive information from the company! "hhse" Making money trading stocks.

    The Wolf Trader: Trading Stocks and Making Money
    Stock alerts from the The Wolf Trader. Stock trading, making money and always looking for the next big money maker.
  • I've been with this company for a long time. Don't expect run ups until just before or after and earnings announcement. If you want to sell, that's the time. Don't wait!
  • Feeling good here
  • Sure would like to see $14-$15 this week!!
  • What's wrong with this share
  • buy more 👍
  • just put this POS up for sale
  • ENDP may close above 50 day moving average today. Short Interest remains above 9%. If it sustains above 50 day, the 200 day MA is now below 14. I don't think the shorts are done trying to push this one lower, but it will be interesting to see where short covering kicks in if the trend continues above 50 and toward the 200 day MA.
  • This is a 20 stock at least. I am IN !!!!
  • we're making higher lows gentleman
  • Option traders have a look at CreditSpreads.io, free live feed of statistically profitable option credit spreads for the following 4 weeks, sometimes including spreads for ENDP! High-probability option credit spreads provide you with an approach to trade with determined risk and the maximum profit gained right away. CreditSpreads.io targets exclusively the option spreads which fulfill its strict standards for probability and profit, and ensures continued profitability by telling you of any approaching situations which can affect the trade. http://www.creditspreads.io

    Sustainable, high probability, defined risk stock option trading opportunities.
  • If FDA mandates change in design portion of it won't that slow down is popularity abuse
  • People! Fact! No tangible product. Erroneous information is the only thing holding it up. Inexperienced people now at helm of sinking ship. They will be used as scapegoats.
  • Why can't they add binders so it is not suitable for snorting are injectable